Yumanity Therapeutics to Present at Upcoming Virtual Investor Conferences

Rhea-AI Summary

BOSTON, May 27, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX) announces that Richard Peters, M.D., Ph.D., President and CEO, will present at two upcoming virtual investor conferences in June. The presentations are scheduled for:

• Jefferies Virtual Healthcare Conference on June 3 at 11:00 AM Eastern Time
• JMP Securities Life Sciences Conference on June 16 at 2:00 PM Eastern Time

A live audio webcast will be accessible on their website, with archived replays available afterward.

BOSTON, May 27, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the following virtual investor conferences in June.

Jefferies Virtual Healthcare Conference

• Thursday, June 3

• 11:00 AM Eastern Time

JMP Securities Life Sciences Conference

• Wednesday, June 16

• 2:00 PM Eastern Time

A live audio webcast of each presentation can be accessed through the Events section of the Company's website at yumanity.com/events. An archived replay of each webcast will be available on the Company's website following the live presentation.

About Yumanity Therapeutics
Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company’s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson’s disease. Yumanity’s drug discovery platform enables the Company to rapidly screen for potential disease-modifying therapies by overcoming the toxicity of misfolded proteins associated with neurogenerative diseases. Yumanity’s pipeline consists of additional programs focused on Lewy body dementia, multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), frontotemporal lobar dementia (FTLD), and Alzheimer’s disease. For more information, please visit www.yumanity.com.

Investors:
Burns McClellan, Inc.
Lee Roth
lroth@burnsmc.com
(212) 213-0006

Media:
Burns McClellan, Inc.
Ryo Imai / Robert Flamm, Ph.D.
rimai@burnsmc.com / rflamm@burnsmc.com
(212) 213-0006 

FAQ

What is Yumanity Therapeutics doing in June 2021?

Yumanity Therapeutics will present at two virtual investor conferences in June 2021.

When is Yumanity Therapeutics presenting at the Jefferies Conference?

Yumanity Therapeutics will present at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 11:00 AM Eastern Time.

What is the date and time for Yumanity's presentation at the JMP Securities Conference?

Yumanity Therapeutics will present at the JMP Securities Life Sciences Conference on June 16, 2021, at 2:00 PM Eastern Time.

Where can I access the webcasts for Yumanity Therapeutics' presentations?

The webcasts for Yumanity Therapeutics' presentations can be accessed on their website in the Events section.

What is the focus of Yumanity Therapeutics in drug development?

Yumanity Therapeutics focuses on innovative, disease-modifying therapies for neurodegenerative diseases.